Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Scandonest Plain

&times

Overview

What is Scandonest Plain?

Mepivacaine hydrochloride, a tertiary amide used as a local anesthetic, is 1-methyl-2', 6'-pipecoloxylidide monohydrochloride with the following structural formula :

C H NO. HCL                                                                        M.W. 282.81

It is a white, crystalline, odorless powder soluble in water, but very resistant to both acid and alkaline hydrolysis.

Levonordefrin, a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions, is (-)-a-(1- Aminoethyl)- 3, 4-dihydroxybenzyl alcohol with the following structural formula :

C H NO                                                                                 M.W. 183.21

It is a white or buff-colored crystalline solid, freely soluble in aqueous solutions of mineral acids, but practically insoluble in water;

DENTAL CARTRIDGES MAY NOT BE AUTOCLAVED.

SCANDONEST 3% PLAIN (mepivacaine hydrochloride injection 3%) and SCANDONEST 2% L (mepivacaine hydrochloride 2% with levonordefrin 1:20,000 injection) are sterile solutions for injection.



What does Scandonest Plain look like?



What are the available doses of Scandonest Plain?

Sorry No records found.

What should I talk to my health care provider before I take Scandonest Plain?

Sorry No records found

How should I use Scandonest Plain?

SCANDONEST is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and children.

As with all local anesthetics the dose varies and depends upon the area to be anesthetized, the vascularity of the tissues, individual tolerance and the technique of anesthesia. The lowest dose needed to provide effective anesthesia should be administered. For specific techniques and procedures refer to standard dental manuals and textbooks.

For infiltration and block injections in the upper or lower jaw, the average dose of 1 cartridge will usually suffice.

Each cartridge contains 1.7 mL (34 mg of 2% or 51 mg of 3%).

5.3 cartridges (180 mg of the 2% solution or 270 mg of the 3% solution) are usually adequate to effect anesthesia of the entire oral cavity. Whenever a larger dose seems to be necessary for an extensive procedure, the maximum dose should be calculated accordlng to the patient's weight. A dose of up to 3 mg per pound of body weight may be administered. At any single dental sitting the total dose for all injected sites should not exceed 400 mg in adults.

The maximum pediatric dose should be

Maxlmum Dose for pediatric population =× Maximum Recommended Dose          150                          For Adults (400 mg)

The following table, approximating these calculations, may also be used as a guide. This table is based upon a recommended maximum for larger pediatric population of 5.3 cartridges (the maximum recommended adult dose) during any single dental sitting, regardless of the child's weight or (for 2 % mepivacaine) calculated maximum amount of drug :

Adapted from Malamed, Stanley F : Handbook of medical emergencies in the dental office, ed. 2, St Louis, 1982. The C V Mosby Co.

When using SCANDONEST for infiltration or regional block anesthesia, injection should always be made slowly and with frequent aspiration.

Any unused portion of a cartridge should be discarded.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


What interacts with Scandonest Plain?

Sorry No Records found


What are the warnings of Scandonest Plain?

Sorry No Records found


What are the precautions of Scandonest Plain?

Sorry No Records found


What are the side effects of Scandonest Plain?

Systemic adverse reactions involving the central nervous system and the cardiovascular system usually result from high plasma levels due to excessive dosage, rapid absorption, or inadvertent intravascular injection.

A small number of reactions may result from hypersensitivity, idiosyncrasy or diminished tolerance to normal dosage on the part of the patient.

Reactions involving the central nervous system are characterized by excitation and/or depression. Nervousness, dizziness, blurred vision, or tremors may occur followed by drowsiness, convulsions, unconsciousness, and possibly respiratory arrest. Since excitement may be transient or absent, the first manifestations may be drowsiness merging into unconsciousness and respiratory arrest.

Cardiovascular reactions

Allergic reactions are rare and may occur as a result of sensitivity to the local anesthetic and are characterized by cutaneous lesions of delayed onset or urticaria, edema and other manifestations of allergy. The detection of sensitivity by skin testing is of limited value. As with other local anesthetics, anaphylactoid reactions to mepivacaine have occurred rarely. The reactions may be abrupt and severe and are not usually dose related. Localized puffiness and swelling may occur.


What should I look out for while using Scandonest Plain?

Mepivacaine is contraindicated in patients with a known hypersensitivity to amide-type local anesthetics.

RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE. (See ).

Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of hypersensitivity.

Fatalities may occur with use of local anesthetics in the head and neck region as the result of retrograde arterial flow to vital CNS areas even when maximum recommended doses are observed. The practitioner should be alert to early evidences of alteration in sensorium or vital signs.

The solution which contains a vasoconstrictor (SCANDONEST 2% L) should be used with extreme caution for patients whose medical history and physical evaluation suggest the existence of hypertension, arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, thyrotoxicosis and diabetes. etc.

The solution which contains a vasoconstrictor (SCANDONEST 2% L) also contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

SCANDONEST 3% PLAIN is sulfite free.


What might happen if I take too much Scandonest Plain?

Treatment of a patient with toxic manifestations consists of assuring and maintaining a patent airway and supporting ventilation (respiration) as required. This usually will be sufficient in the management of most reactions. Should a convulsion persist despite ventilatory therapy, small increments of anticonvulsive agents may be given intravenously, such as benzodiazepine (e.g . diazepam) or ultrashort-acting barbiturates (e.g. thiopental, or thiamylal) or short-acting barbiturates (e.g. pentobarbital or secobarbital). Cardiovascular depression may require circulatory assistance with intravenous fluids and/or vasopressor (e.g. ephedrine) as dictated by the clinical situation. Allergic reactions should be managed by conventional means.

Intravenous and subcutaneous LD's in mice for mepivacaine hydrochloride 3% are 33 and 258 mg/kg, respectively. The acute IV and SC LD's in mice for mepivacaine hydrochloride 2% with levonordefrin 1:20,000 are 30 and 184 mg/kg, respectively.


How should I store and handle Scandonest Plain?

- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.- SCANDONEST 2% L (Mepivacaine Hydrochoride and Levonordefrin injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1097-8).- SCANDONEST 3%Plain (Mepivacaine hydrochoride injection, USP), is available in cardboard boxes containing 5 blisters of 10 × 1.7 mL dental cartridges, 50 per cartons (NDC 12862-1098-9).Store at room temperature, below 25°C (77°F). Protect from light. Do not permit to freeze.CANS : For protection from light, retain in can until time of use. Once opened, the can should be reclosed using the plastic cap.BOXES : For protection from light, retain in box until time of use. Once opened, the box should be reclosed by closing the top flap.SCANDONEST 2%L should not be use if color is pinkish or darker than slightly yellow or if it contains a precipitate.Cartridge warmers should not be used with SCANDONEST products.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

SCANDONEST stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia.

SCANDONEST is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the urine. SCANDONEST, because of its amide structure, is not detoxified by the circulating plasma esterases. The liver is the principal site of metabolism, with over 50 percent of the administered dose being excreted into the bile as metabolites. Most of the metabolized mepivacaine is probably resorbed in the intestine and then excreted into the urine since only a small percentage is found in the feces. The principal route of excretion is via the kidney. Most of the anesthetic and its metabolites are eliminated within 30 hours. It has been shown that hydroxylation and N-demethylation, which are detoxification reactions, play important roles in the metabolism of the anesthetic. Three metabolites of mepivacaine have been identified from adult humans : two phenols, which are excreted almost exclusively as their glucuronide conjugates, and the N-demethylated compound (2', 6'-pipecoloxylidide).

The onset of action is rapid (30 to 120 seconds in the upper jaw ; 1 to 4 minutes in the lower jaw) and SCANDONEST 3% PLAIN will provide operating anesthesia of in the and 40 minutes in the lower jaw.

SCANDONEST 2% L with levonordefrin 1:20,000 provides anesthesia of longer duration for more prolonged procedures, in the and 2.5 hours to 5.5 hours in the lower jaw.

SCANDONEST does not ordinarily produce irritation or tissue damage.

Levonordefrin is a sympathomimetic amine used as a vasoconstrictor in local anesthetic solutions. It has pharmacologic activity similar to that of epinephrine but it is more stable than epinephrine. In equal concentrations, levonordefrin is less potent than epinephrine in raising blood pressure, and as a vasoconstrictor.

Non-Clinical Toxicology
Mepivacaine is contraindicated in patients with a known hypersensitivity to amide-type local anesthetics.

RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE. (See ).

Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of hypersensitivity.

Fatalities may occur with use of local anesthetics in the head and neck region as the result of retrograde arterial flow to vital CNS areas even when maximum recommended doses are observed. The practitioner should be alert to early evidences of alteration in sensorium or vital signs.

The solution which contains a vasoconstrictor (SCANDONEST 2% L) should be used with extreme caution for patients whose medical history and physical evaluation suggest the existence of hypertension, arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, thyrotoxicosis and diabetes. etc.

The solution which contains a vasoconstrictor (SCANDONEST 2% L) also contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

SCANDONEST 3% PLAIN is sulfite free.

The administration of local anesthetic solutions containing vasopressors, such as levonordefrin, epinephrine or norepinephrine, to patients receiving tricyclic antidepressants or monoamine oxidase inhibitors produce severe prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.

Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.

Solutions containing a vasoconstrictor should be used cautiously in the presence of diseases which may adversely affect the patient's cardiovascular system. Serious cardiac arrhythmias may occur if preparations containing a vasoconstrictor are employed in patients during or following the administration of potent inhalation anesthetics.

Mepivacaine SHOULD BE USED WITH CAUTION IN PATIENTS WITH KNOWN DRUG ALLERGIES AND SENSITIVITIES. A thorough history of the patient's prior experience with mepivacaine or other local anesthetics as well as concomitant or recent drug use should be taken (see ). Patients allergic to methylparaben or paraaminobenzoic acid derivatives (procaine, tetracaine, benzocaine, ect.) have not shown cross-sensitivity to agents of the amide type such as mepivacaine. Since mepivacaine is metabolized in the liver and excreted by the kidneys, it should be used cautiously in patients with liver and renal disease.

Array

The safety and effectiveness of mepivacaine depend upon proper dosage, correct technique, adequate precautions, and readiness for emergencies.

The lowest dose that results in effective anesthesia should be used to avoid high plasma levels and possible adverse effects. Injection of repeated doses of mepivacaine may cause significant increase in blood levels with each repeated dose due to slow accumulation of the drug or its metabolites, or due to slower metabolic degradation than normal.

Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their weight and physical status.

Mepivacaine should be used with caution in patients with a history of severe disturbances of cardiac rhythm or heart block.

INJECTIONS SHOULD ALWAYS BE MADE SLOWLY WITH ASPIRATION TO AVOID INTRAVASCULAR INJECTION AND THEREFORE SYSTEMIC REACTION TO BOTH LOCAL ANESTHETIC AND VASOCONSTRICTOR.

If sedatives are employed to reduce patient apprehension, use reduced doses, since local anesthetic agents, like sedatives, are central nervous system depressants which in combination may have an additive effect. Young children should be given minimal doses of each agent.

Changes in sensorium such as excitation, disorientation, drowsiness, may be early indications of a high blood level of the drug and may occur following inadvertent intravascular administration or rapid absorption of mepivacaine.

Local anesthetic procedures should be used with caution when there is inflammation and/or sepsis in the region of the proposed injection.

Systemic adverse reactions involving the central nervous system and the cardiovascular system usually result from high plasma levels due to excessive dosage, rapid absorption, or inadvertent intravascular injection.

A small number of reactions may result from hypersensitivity, idiosyncrasy or diminished tolerance to normal dosage on the part of the patient.

Reactions involving the central nervous system are characterized by excitation and/or depression. Nervousness, dizziness, blurred vision, or tremors may occur followed by drowsiness, convulsions, unconsciousness, and possibly respiratory arrest. Since excitement may be transient or absent, the first manifestations may be drowsiness merging into unconsciousness and respiratory arrest.

Cardiovascular reactions

Allergic reactions are rare and may occur as a result of sensitivity to the local anesthetic and are characterized by cutaneous lesions of delayed onset or urticaria, edema and other manifestations of allergy. The detection of sensitivity by skin testing is of limited value. As with other local anesthetics, anaphylactoid reactions to mepivacaine have occurred rarely. The reactions may be abrupt and severe and are not usually dose related. Localized puffiness and swelling may occur.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).